Europe's Top 5 Biotech Hotspots

FierceBiotech's Europe's Top 5 Biotech Hotspots

For decades European countries have been among the most innovative on the planet when it comes to drug development. So our siste publication FierceBiotech is taking a look at the development scene solely in Europe to see which countries have hatched the best programs to support drug discovery and innovation. Click here to see our picks for the top 5 drug development hotspots in Europe. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.